Nitric oxide in tumor biology and cancer therapy. Part 2: Therapeutic implications.
Tozer
G M
GM
Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, Northwood, UK.
Everett
S A
SA
D000818:Animals; D001783:Blood Flow Velocity / Q000187:drug effects / Q000502:physiology; D002455:Cell Division; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D008833:Microcirculation / Q000187:drug effects; D019331:NG-Nitroarginine Methyl Ester / Q000627:therapeutic use; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D009374:Neoplasms, Experimental / Q000098:blood supply / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D009569:Nitric Oxide / Q000502:physiology*; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D018384:Oxidative Stress; D016896:Treatment Outcome
D004791:Enzyme Inhibitors; D009569:Nitric Oxide; D019001:Nitric Oxide Synthase; D019331:NG-Nitroarginine Methyl Ester